272 related articles for article (PubMed ID: 21481826)
1. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.
Bartolucci AA; Tendera M; Howard G
Am J Cardiol; 2011 Jun; 107(12):1796-801. PubMed ID: 21481826
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
Bartolucci AA; Howard G
Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
[TBL] [Abstract][Full Text] [Related]
3. An update on aspirin in the primary prevention of cardiovascular disease.
Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
[TBL] [Abstract][Full Text] [Related]
4. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
[TBL] [Abstract][Full Text] [Related]
5. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
[TBL] [Abstract][Full Text] [Related]
6. [Effects of low-dose aspirin on primary prevention of cardiovascular events: a systematic review].
Tang HQ; Yang LL; Hu SL; Shen G; Sun YH; Huang XH; Li JH; Xu TJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Apr; 38(4):315-20. PubMed ID: 20654075
[TBL] [Abstract][Full Text] [Related]
7. Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials.
Kunutsor SK; Seidu S; Khunti K
Diabet Med; 2017 Mar; 34(3):316-327. PubMed ID: 27086572
[TBL] [Abstract][Full Text] [Related]
8. The aspirin controversy in primary prevention.
Raju NC; Eikelboom JW
Curr Opin Cardiol; 2012 Sep; 27(5):499-507. PubMed ID: 22874127
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
10. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
11. Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Liu S; Eckstein J; Lam A; Cheema AN
Curr Vasc Pharmacol; 2023; 21(2):111-119. PubMed ID: 36718966
[TBL] [Abstract][Full Text] [Related]
12. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials.
O'Fee K; Deych E; Ciani O; Brown DL
JAMA Intern Med; 2021 Dec; 181(12):1575-1587. PubMed ID: 34694318
[TBL] [Abstract][Full Text] [Related]
14. Prevention of cardiovascular disease: risks and benefits of aspirin.
Buring JE; Hennekens CH
J Gen Intern Med; 1990; 5(5 Suppl):S54-7. PubMed ID: 2231066
[TBL] [Abstract][Full Text] [Related]
15. Clinical Inquiries: What are the benefits and risks of daily low-dose aspirin for primary prevention of CV events?
Mutter J; Grandy R; Hulkower S; Stigleman S
J Fam Pract; 2018 Apr; 67(4):247-248. PubMed ID: 29614147
[TBL] [Abstract][Full Text] [Related]
16. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am Heart J; 1999 Apr; 137(4 Pt 2):S9-S13. PubMed ID: 10097241
[TBL] [Abstract][Full Text] [Related]
17. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
Hennekens CH; Schneider WR
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
[TBL] [Abstract][Full Text] [Related]
18. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis.
Stavrakis S; Stoner JA; Azar M; Wayangankar S; Thadani U
Am J Med Sci; 2011 Jan; 341(1):1-9. PubMed ID: 21191260
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
20. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
